ZA200203095B - Biphenyl derivatives used as NHE-3 inhibitors. - Google Patents

Biphenyl derivatives used as NHE-3 inhibitors.

Info

Publication number
ZA200203095B
ZA200203095B ZA200203095A ZA200203095A ZA200203095B ZA 200203095 B ZA200203095 B ZA 200203095B ZA 200203095 A ZA200203095 A ZA 200203095A ZA 200203095 A ZA200203095 A ZA 200203095A ZA 200203095 B ZA200203095 B ZA 200203095B
Authority
ZA
South Africa
Prior art keywords
nhe
inhibitors
derivatives used
biphenyl derivatives
biphenyl
Prior art date
Application number
ZA200203095A
Inventor
Dieter Dorsch
Norbert Beier
Peter Raddatz
Claudia Wilm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200203095B publication Critical patent/ZA200203095B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
ZA200203095A 1999-09-22 2002-04-18 Biphenyl derivatives used as NHE-3 inhibitors. ZA200203095B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19945302A DE19945302A1 (en) 1999-09-22 1999-09-22 Biphenyl derivatives as NHE-3 inhibitors

Publications (1)

Publication Number Publication Date
ZA200203095B true ZA200203095B (en) 2003-09-23

Family

ID=7922831

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203095A ZA200203095B (en) 1999-09-22 2002-04-18 Biphenyl derivatives used as NHE-3 inhibitors.

Country Status (16)

Country Link
EP (1) EP1214291A1 (en)
JP (1) JP2004500338A (en)
KR (1) KR20020033818A (en)
CN (1) CN1555356A (en)
AU (1) AU7649700A (en)
BR (1) BR0014199A (en)
CA (1) CA2387529A1 (en)
CZ (1) CZ2002815A3 (en)
DE (1) DE19945302A1 (en)
HU (1) HUP0202891A3 (en)
MX (1) MXPA02003087A (en)
NO (1) NO20021407D0 (en)
PL (1) PL355097A1 (en)
SK (1) SK3342002A3 (en)
WO (1) WO2001021582A1 (en)
ZA (1) ZA200203095B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163239A1 (en) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
DE10304374A1 (en) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic agent and medicament containing them
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10341240A1 (en) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituted thienoimidazoles, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
DE102005001411A1 (en) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
ATE479679T1 (en) 2007-06-28 2010-09-15 Sanofi Aventis Us Llc METHOD FOR PRODUCING N-(2-CHLORINE-4-METHYL-3-THIENYL)-1H-BENZIMIDAZOLE-2-AMINE HYDROCHLORIDE AND INTERMEDIATE PRODUCTS THEREFOR
MX2011001821A (en) 2008-09-02 2011-03-25 Sanofi Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX345283B (en) 2008-12-31 2017-01-24 Ardelyx Inc Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders.
ES2628850T3 (en) 2011-03-15 2017-08-04 Astellas Pharma Inc. Guanidine compound
CN103012200B (en) * 2011-09-20 2014-12-17 北京大学 Compound with beta-secretase inhibition function, preparation method and applications thereof
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20230132619A (en) 2013-04-12 2023-09-15 알데릭스, 인코포레이티드 Nhe3-binding compounds and methods for inhibiting phosphate transport
US9932331B2 (en) 2014-07-25 2018-04-03 Taisho Pharmaceutical Co., Ltd. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
JP7292207B2 (en) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド Compounds Useful for Treating Gastrointestinal Disorders
MX2020001412A (en) 2017-08-04 2020-08-03 Ardelyx Inc Glycyrrhetinic acid derivatives for treating hyperkalemia.
TW202045523A (en) 2019-02-07 2020-12-16 美商阿德利克斯公司 Compounds and methods for treating hyperkalemia
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548812A1 (en) * 1995-12-27 1997-07-03 Hoechst Ag Use of inhibitors of the cellular Na · + · / H · + · exchanger (NHE) for the manufacture of a medicament for respiratory stimulation
DE19622222A1 (en) * 1996-06-03 1997-12-04 Hoechst Ag Use of sodium=proton exchange inhibitor
DE19737224A1 (en) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmaceutical preparation for cardiovascular treatment
DE19819548A1 (en) * 1998-04-30 1999-11-04 Merck Patent Gmbh Biphenyl derivatives

Also Published As

Publication number Publication date
PL355097A1 (en) 2004-03-22
AU7649700A (en) 2001-04-24
CN1555356A (en) 2004-12-15
BR0014199A (en) 2002-05-21
HUP0202891A2 (en) 2003-02-28
KR20020033818A (en) 2002-05-07
JP2004500338A (en) 2004-01-08
CZ2002815A3 (en) 2002-08-14
CA2387529A1 (en) 2001-03-29
WO2001021582A1 (en) 2001-03-29
DE19945302A1 (en) 2001-03-29
NO20021407L (en) 2002-03-21
SK3342002A3 (en) 2002-07-02
HUP0202891A3 (en) 2003-11-28
MXPA02003087A (en) 2003-08-20
NO20021407D0 (en) 2002-03-21
EP1214291A1 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
ZA200203095B (en) Biphenyl derivatives used as NHE-3 inhibitors.
ZA200202775B (en) Quinazoline derivatives as VEGF inhibitors.
SI1686119T1 (en) Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
GB9900416D0 (en) Inhibitors
MXPA03005838A (en) Vla-4 inhibitors.
HUP0202713A3 (en) Pteridinones as kinase inhibitors
ZA200109890B (en) Metalloprotease inhibitors.
HK1041407A1 (en) Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors.
HUP0202450A3 (en) N-heterocyclic derivatives as nos inhibitors
ZA200108735B (en) Renin inhibitors.
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
ZA200204397B (en) Nitrile derivatives as cathepsin K inhibitors.
MXPA01013406A (en) Vla-4 inhibitor compounds.
HK1046278A1 (en) Pyrazolobenzodiazepines as cdk2 inhibitors.
IL149097A0 (en) 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor
MXPA02005067A (en) Inhibitor compositions.
AU6381701A (en) Bisamidino compounds as nhe-3 inhibitors
HK1047434A1 (en) Thienopyrimidines as phosphodiesterase inhibitors.
HK1047276A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
ZA200110053B (en) Factor via inhibitors.
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
HK1042695A1 (en) Prothease inhibitors
ZA200007405B (en) Angiogenesis inhibitors.
GB2389113B (en) B-secretase inhibitor